Nonspherical metal-based nanoarchitectures: Synthesis and impact of size, shape, and composition on their biological activity
As an initial test of the ability of 6-AH family members to alter HGF-dependent cellular activity we evaluated the capacity of several members of the family to modify the proliferative activity of Madin-Darby canine kidney (MDCK) cells, a standard cellular model for investigating the HGF/Met system (Stella and Comoglio, 1999)
KLOW peptide is a research blend combining KPV, BPC-157, TB-500, and GHK-Cu into a single 80 mg vial
Efficacy, safety, and tolerability of the low glycemic index treatment in pediatric epilepsy
10.1164/ajrccm.149.2.7508323
In phase 1 studies, brensocatib reduced NE levels in blood with acceptable safety and pharmacokinetics (194, 201), prompting a 24-week phase 2 WILLOW trial conducted in 256 patients with bronchiectasis, in which treatment with 10 mg or 25 mg of brensocatib daily for 24 weeks significantly prolonged time to exacerbations compared with placebo (115, 202)
